Affinity Asset Advisors, LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Affinity Asset Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$7.58 - $12.25 $1.15 Million - $1.87 Million	-152,323 Reduced 54.73%	125,969 $1.54 Million
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $894,999 - $1.14 Million	100,000 Added 56.09%	278,292 $2.68 Million
Q2 2023 Aug 14, 2023	SELL	$7.73 - $10.57 $231,900 - $317,100	-30,000 Reduced 14.4%	178,292 $1.6 Million
Q1 2023 May 15, 2023	BUY	$6.3 - $8.39 $126,000 - $167,800	20,000 Added 10.62%	208,292 $1.64 Million
Q4 2022 Feb 13, 2023	BUY	$4.2 - $14.24 $386,290 - $1.31 Million	91,974 Added 95.49%	188,292 $1.27 Million
Q3 2022 Nov 14, 2022	BUY	$9.85 - $16.83 $948,732 - $1.62 Million	96,318 New	96,318 $1.4 Million
Q3 2021 Nov 12, 2021	SELL	$17.11 - $24.49 $855,500 - $1.22 Million	-50,000 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$23.12 - $29.91 $1.16 Million - $1.5 Million	-50,000 Reduced 50.0%	50,000 $1.2 Million
Q1 2021 May 14, 2021	BUY	$14.69 - $42.57 $807,950 - $2.34 Million	55,000 Added 122.22%	100,000 $2.57 Million
Q4 2020 Feb 12, 2021	BUY	$12.88 - $19.47 $579,600 - $876,150	45,000 New	45,000 $855,000

126

47.9M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $204M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.